Alnylam

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Oct 31,2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 31, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

  • 26th Annual Credit Suisse Healthcare Conference onWednesday, November 8, 2017 at 8:40 am MT (10:40 am ET) at the Phoenician Hotel in Scottsdale, Arizona
  • 29th Annual Piper Jaffray Healthcare Conference onWednesday, November 29, 2017 at 8:30 am ET at the Lotte New York Palace Hotel in New York City
  • Evercore ISI BioPharma Catalyst/Deep Dive Conference on Wednesday, November 29, 2017 at 9:30 am ET at the Boston Harbor Hotel in Boston

A live audio webcast of each presentation will be available on the Investors section of the Company’s website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 600 people in the U.S. and Europe and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.

Source: Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.
Investors and Media
Christine Regan Lindenboom, 617-682-4340
or
Investors
Josh Brodsky, 617-551-8276